Stay updated on Pembrolizumab Amurubicin Combo in Refractory SCLC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Amurubicin Combo in Refractory SCLC Clinical Trial page.

Latest updates to the Pembrolizumab Amurubicin Combo in Refractory SCLC Clinical Trial page
- CheckyesterdayNo Change Detected
- Check9 days agoChange DetectedFooter now shows Revision: v3.3.3; references to HHS Vulnerability Disclosure and Revision: v3.3.2 have been removed.SummaryDifference0.1%

- Check16 days agoNo Change Detected
- Check23 days agoNo Change Detected
- Check30 days agoChange DetectedThe page now displays Revision: v3.3.2, replacing Revision: v3.3.1.SummaryDifference0.1%

- Check37 days agoChange DetectedThe Publications note now states that publications are automatically filled in from PubMed, replacing the previous wording. The revision tag was updated to Revision: v3.3.1 (replacing v3.2.0).SummaryDifference0.1%

- Check44 days agoChange DetectedRemoved the government funding status banner from the page; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check59 days agoChange DetectedNo additions or deletions were detected for the Study Details page (NCT03253068). The content appears unchanged.SummaryDifference0.5%

- Check88 days agoChange DetectedPage updated from Revision: v3.0.2 to Revision: v3.2.0.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab Amurubicin Combo in Refractory SCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Amurubicin Combo in Refractory SCLC Clinical Trial page.